Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO #ADAP #Adaptimmune #Biotechnology #Celltherapy #Chemicals #ESMO23 #HealthCare #Investing #NASDAQ #Oncology
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers75% response rate in ovarian, urothelial, and head & neck cancers in patients who received three or fewer prior lines of therapyAcceptable benefit-to-risk profile with ADP-A2M4CD8 next-generation monotherapy and in combination with the checkpoint...
http://dlvr.it/Sxq3gX
http://dlvr.it/Sxq3gX
Comments
Post a Comment